Clinical trials: Granulocyte Colony-stimulating Factor (G-CSF) Mobilized
Adult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Lymphomatoid Granulomatosis
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
This clinical trial studies etoposide, filgrastim and plerixafor in improving stem cell mobilization in patients with non-Hodgkin lymphoma.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
- Trial name
- NCT01408043
- Testing
- plerixafor, filgrastim, etoposide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Case Comprehensive Cancer Center
Fanconi Anemia
Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1
Fanconi anemia (FA) is a congenital disease characterized by bone marrow failure and increased incidence of malignant tumors. The Project pursue the optimization of the collection of hematopoietic progenitor cells for later use…
- Trial name
- NCT02931071
- Testing
- filgrastim, plerixafor
- Where
- 2 sites in Spain
- Volunteers
- 13 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Leukemia
G-CSF in Stimulating Peripheral Stem Cells for Autologous Stem Cell Transplant in Treating Patients With Chronic Phase Chronic Myeloid Leukemia in Complete Remission
RATIONALE: Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored until transplant.
- Trial name
- NCT00233961
- Testing
- filgrastim
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Granulocyte Colony-Stimulating Factor
The Value of Peripheral Blood CD34+ Cell Dynamics Monitoring in Autologous Hematopoietic Stem Cell Transplant Mobilization
The aim of this study was to evaluate the difference in the accuracy of CD34+ cell detection by immunomagnetic bead method and flow cytometry in patients with hematologic malignancies pre-treated with stem cell transplantation…
- Trial name
- NCT05970185
- Testing
- PEG-rhG-CSF, G-CSF
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhongnan Hospital
Breast Cancer, Gestational Trophoblastic Tumor
Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors
RATIONALE: Interleukin-11 and filgrastim stimulate the production of blood cells. Giving these drugs to stimulate peripheral stem cells that can be collected for peripheral stem cell transplantation may result in fewer side…
- Conditions
- Breast Cancer, Gestational Trophoblastic Tumor, Kidney Cancer, Lymphoma
- Trial name
- NCT00004157
- Testing
- filgrastim, recombinant interleukin-11
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Granulocyte Colony-stimulating Factor, Stem Cell Mobilization
A Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for PEG-G-CSF
Have a comparison between pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) and recombinant human granulocyte-colony stimulating factor (rhG-CSF) for difference in efficacy of hematopoietic…
- Trial name
- NCT05409547
- Testing
- PEG-rhG-CSF
- Volunteers
- 80 people
- Sponsor
- Ning Huang
Non-Hodgkin's Lymphoma
A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate the ability of two different fixed doses of pegfilgrastim (6mg and 12mg) and a by-weight dose of filgrastim (5ug/kg/day) for the mobilisation and collection of PBPCs for autologous…
- Trial name
- NCT00117455
- Testing
- pegfilgrastim, filgrastim
- Sponsor
- Amgen
Hematologic Diseases
A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF
This is a study involving patients who are undergoing allogeneic peripheral blood stem cell transplantation. Both donors and recipients are being sought for this study.
- Trial name
- NCT00208949
- Testing
- G-CSF, GM-CSF
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Emory University
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma
RATIONALE: There are different methods of stem cell mobilization, such as using colony-stimulating factors alone or following chemotherapy priming.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01074060
- Testing
- plerixafor, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma
Primary Objective: To determine if Multi Myeloma (MM) patients mobilized with granulocyte colony-stimulating factor (G-CSF) plus plerixafor 240 μg/kg are more likely to achieve a target number of greater than or equal to 6 x 10^6…
- Trial name
- NCT02221479
- Testing
- plerixafor GZ316455, Filgrastim
- Where
- 5 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Genzyme, a Sanofi Company
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
This phase II trial is studying how well giving bendamustine hydrochloride, etoposide, dexamethasone, and filgrastim together for peripheral stem cell mobilization works in treating patients with refractory or recurrent lymphoma…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01110135
- Testing
- bendamustine hydrochloride, dexamethasone, filgrastim
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Washington
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT02037256
- Testing
- bortezomib, filgrastim, autologous hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Healthy Allogeneic Donors, Granulocyte Colony-stimulating Factor (G-CSF) Mobilized
Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®
The study will determine the advantage of the Spectra Optia® IDL set compared to the standard collection set for collection of peripheral blood progenitor cells using the Spectra Optia® apheresis system.
- Trial name
- optiMaL (NCT01901458)
- Testing
- Spectra Optia® IDL-Set, Spectra Optia® Collection Set
- Where
- 2 sites in Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Acute on Chronic Liver Failure
Granulocyte Colony Stimulating Factor(G-CSF) Therapy for Patients With ACLF
The purpose of the study is to determine whether Granulocyte Colony Stimulating factor(G-CSF) therapy is effective in the treatment of patients with Acute on chronic liver failure(ACLF).
- Trial name
- NCT01036932
- Testing
- Granulocyte Colony Stimulating Factor, Normal Saline
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Govind Ballabh Pant Hospital
Hematopoietic Stem Cell Transplantation
NOX-A12 Multiple Ascending Dose Study in Healthy Volunteers
This is the second clinical study of NOX-A12. This study intends to provide information on the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of repeated intravenous doses of NOX-A12 (2.0 and 4.0 mg/kg/d)…
- Trial name
- SNOXA12C101 (NCT01194934)
- Testing
- NOX-A12, Filgrastim, NOX-A12 in combination with Filgrastim
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- TME Pharma AG
Healthy
Comparison of Quality and Quantity of M-PRP Cellular Content Filgrastim vs. Pegfilgrastim
The goal of this prospective, observational study is to compare the quality and quantity of the cellular content of platelet-rich plasma harvested after administering one of two cell-stimulating proteins, filgrastim and…
- Trial name
- M-PRP (NCT05573386)
- Testing
- Filgrastim, Pegfilgrastim
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Andrews Research & Education Foundation
Lymphoma
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002461
- Testing
- filgrastim, sargramostim, carmustine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Montefiore Medical Center
Blood Diseases
Efficacy of Biosimilar Filgrastim on the Mobilization of Hematopoietic Stem Cell CD34+ (Cluster of Differentiation 34) and on the Kinetic Engraftment
The endogenous growth factor granulocyte (G-CSF) stimulates the proliferation and differentiation of hematopoietic progenitors commissioned to mature as neutrophils and activated granulocytes mature neutrophils.
- Trial name
- NCT02806791
- Testing
- FILGRASTIM
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Lymphoma, Hodgkin's Lymphoma
Pegfilgrastim PBPC Mobilization Study
This is a randomized, double-blind, multi-center study to assess the safety and effectiveness of using a single subcutaneous (under the skin) injection of pegfilgrastim or daily subcutaneous injections of Filgrastim to mobilize…
- Conditions
- Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Hematology
- Trial name
- NCT00066092
- Testing
- pegfilgrastim 12 mg, filgrastim, pegfilgrastim 6 mg
- Volunteers
- 41 people
- Sponsor
- Amgen
Leukemia
Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>
RATIONALE: Transplanted peripheral stem cells can sometimes be rejected by the body's tissues. Treating donor peripheral stem cells with filgrastim may increase the number of donor white blood cells.
- Trial name
- NCT00025545
- Testing
- cyclophosphamide, methotrexate, peripheral blood stem cell transplantation
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center